In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pharmaceutical Strategic Outlook: The Trouble with Alliances

Executive Summary

At Windhover's March 2008 Pharmaceutical Strategic Outlook meeting one overriding theme was an alliance paradox: values continue to rise and deals provide an increasingly important source of funds for biotechs, yet public investors don't seem to like these deals. Plus: a discussion of big-pharma outlicensing and the importance of CFOs in pharma strategy.
Advertisement

Related Content

Dealmaking When Pharma's the Only Game in Town
Phase II Alliances Command the Most Interest
Royalty Flush: Why Monetizing Tomorrow's Revenue Stream Today Could Catch on in a Big Way
Best of the Blog: IN VIVO, June 2008
Pharma's New Follow-On Strategy
Alnylam Takes Platform Monetization to a Whole New and Non-Exclusive Level
Alnylam Takes Platform Monetization to a Whole New and Non-Exclusive Level
Lilly's Chorus Experiment
BMS Deals Diabetes Drugs, Solidifies Specialist Stance
Pharmaceutical Strategic Alliances 2006: Forcing Externalization at Big Pharma

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV003105

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel